Result of AGM

Electrical Geodesics, Inc.

AGM Results

EUGENE, OREGON, US, 21 June 2016 - Electrical Geodesics, Inc. ("EGI" or the "Company"), a leading neurodiagnostic medical technology company, today announces that all of the resolutions set out in the Company's Notice of Annual General Meeting (the "Meeting") issued to stockholders on 4 May 2016 were passed by stockholders at the Meeting held in Eugene at 9.30 PST yesterday. The Annual Report and Accounts for the year ended 31 December 2015 were also received by the meeting.

Don Tucker, CEO of EGI, addressed the meeting briefly, summarising the information on the progress of EGI set out within the 2015 Annual Report. He added: "We will provide detailed comment on current trading early in July with an update on our first six months operations. Our major development projects are progressing well and we believe we can deliver new products to the market in the near term in time to meet our sales targets for 2016."

Proxy Voting Results

Proxy and actual voting results in respect of Ordinary Resolutions 1 to 4 are shown below. Votes were received from holders of 21,188,186 shares representing 77% of the issued share capital.

Ordinary Resolutions

1.a To reappoint Don Tucker as a director

1.b To reappoint Ann Bunnenberg as a director

1.c To reappoint Christine Soden as a director

1.d To reappoint John Brown as a director

1.e To reappoint Raymond Englander as a director

2. To re-appoint Peterson Sullivan LLP as auditors of the Company.

3. To authorise the Directors of the Company to determine the remuneration of the auditors.

4. To amend the Electrical Geodesics, Inc., 2013 Equity Incentive Plan to increase the number of shares of Common Stock that may be issued under that plan from 1,711,415 shares to 1,926,800.

Copies of all resolutions and all documents referred to above are available on the Company's website at www.egi.com. 

For more information contact:

About EGI

Founded in 1992, EGI designs, develops and commercialises a range of non-invasive neurodiagnostic products used to monitor and interpret brain activity based on its proprietary dense array electroencephalography ("dEEG") platform technology. The Company's technology uses up to 256 sensors, providing much higher resolution brain activity data compared to conventional 8 or 16 channel EEG and is used in medical, clinical and research settings in a diverse range of applications including important areas such as the diagnosis and monitoring of epilepsy, neurosurgical planning, sleep assessment, and many others.

EGI's dense array technology capitalizes on the Company's unique Hydrocel Geodesic Sensor Net which allows faster, easier, and more convenient placement of many EEG sensors in an even distribution over the entire scalp, providing more accurate and precise diagnosis and measurement. EGI's technology is now widely used in neuroscience research laboratories and is becoming more commonly used in clinics, care centers, and hospitals around the world. Data is measured and visualised using EGI's proprietary amplifier technology and software, providing a complete, advanced, high-resolution EEG platform. The Company's products are compatible with multiple diagnostic and imaging technologies, including magnetic resonance (MR) imaging, functional MRI (fMRI), and magneto-encephalography (MEG).

In April 2013 EGI commenced trading on the London Stock Exchange AIM market under the symbol EGI.L. See www.egi.com for more information on the Company.